Baidu
map
DRUG DISCOV TODAY 润色咨询

DRUG DISCOVERY TODAY

出版年份：1996 年文章数：2767 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：2.6% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2022-08-23 ms1000001457809000

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤
    经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2024-01-22 P拾荒者 来自浙江省

    只接受约稿，哎

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2022-07-20 嘎嘎S

    只接受约稿吗

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2021-12-29 ms6000000264964247

    比较适合科研小白练手的SCI文章类型有哪些？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2021-12-27 MS54455111222

    researcharticle和其它文章类型有什么区别？

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2020-06-04 ms1011445849213233

    还没投就因为没法提供wb原图放弃投稿了，血泪教训

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2020-05-04 ms8805891246354106

    审稿速度:2.0
    经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it.

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2020-02-06 146f6ef6m90(暂无昵称)

    。。看了半天才发现只接受约稿

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2019-12-13 ms4591412325009157

    submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references.

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1240571, encodeId=440512405e1eb, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：好的topic可以自己去写信proposal，editor比较nice，中了一篇比较editor认可第二年收到了邀稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f02c8290054, createdName=ms1000001457809000, createdTime=Tue Aug 23 19:14:49 CST 2022, time=2022-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183289, encodeId=289e218328944, content=只接受约稿，哎, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Jan 22 21:31:27 CST 2024, time=2024-01-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1233605, encodeId=b79712336050e, content=只接受约稿吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72fc5543994, createdName=嘎嘎S, createdTime=Wed Jul 20 13:21:45 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089800, encodeId=4d4310898006b, content=比较适合科研小白练手的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089799, encodeId=11e21089e99a8, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861456, encodeId=e38d8614565b, content=还没投就因为没法提供wb原图放弃投稿了，血泪教训 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93775414031, createdName=ms1011445849213233, createdTime=Thu Jun 04 23:44:56 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=860156, encodeId=49bb860156d9, content=审稿速度:2.0<br>经验分享：i submitted 1-2 articles to this journal each year. my first second article about silver nanoparticles was published in 2015, and it got citation more than 400 times. this makes the editor like to have my lab's articles. until now, i had published 6-8 articles, and never be rejected. it is a wonderful journal without publication charge. i love it. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a2c5414126, createdName=ms8805891246354106, createdTime=Mon May 04 05:09:44 CST 2020, time=2020-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=584306, encodeId=a235584306d5, content=。。看了半天才发现只接受约稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd2b5180633, createdName=146f6ef6m90(暂无昵称), createdTime=Thu Feb 06 00:00:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=855770, encodeId=a358855e7093, content=submission to drug discovery today is by invitation only. if you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e55414120, createdName=ms4591412325009157, createdTime=Fri Dec 13 15:29:37 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563067, encodeId=15c556306e59, content=从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQplhxTRO3b5LyTPoSic9FreAibffXTuxIic9B71NgicGczs4yXWYXZTNtzJcibXda5SjY3ghpomibKBty2Jg/0, createdBy=fc962079411, createdName=柳叶刀q, createdTime=Sun Nov 11 12:25:00 CST 2018, time=2018-11-11, status=1, ipAttribution=)]
    2018-11-11 柳叶刀q

    从投到发大概需要多久啊spanclassquote138018320170716发表brSCI20146691SCI20155625SCI20166369赚翻了去年发表了一篇今年就突破6分亲们你们也需要有这样的眼光哦span

    0

共21条页码: 1/3页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map